Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 20/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767160 | 0.99 | ERN1 (1.00) | ERN1 | |
| SCHEMBL12767165 | 0.90 | ERN1 (1.00) | ERN1 | |
| SCHEMBL12767129 | 0.90 | ERN1 (1.00) | ERN1 | |
| SCHEMBL12674877 | 0.90 | ERN1 (0.81) | ERN1 | |
| SCHEMBL12675795 | 0.84 | ERN1 (0.83) | ERN1 | |
| SCHEMBL14924956 | 0.84 | ERN1 (0.70) | ERN1 | |
| SCHEMBL12767131 | 0.82 | ERN1 (1.00) | ERN1 | |
| SCHEMBL18717317 | 0.81 | ERN1 (0.79) | ERN1 | |
| SCHEMBL12767149 | 0.81 | ERN1 (1.00) | ERN1 | |
| SCHEMBL12674891 | 0.80 | ERN1 (0.66) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496230-B1 | IRE-1 ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-02-26 | — | — | EP | disclosed |
| US-20180072745-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072745-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-9856266-B2 | IRE-1alpha inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-02 | — | — | US | disclosed |
| US-20170166576-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-15 | — | — | US | disclosed |
| US-20170166576-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-15 | — | — | US | disclosed |
| US-9493435-B2 | IRE-1α inhibitors | MANNKING CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493435-B2 | IRE-1α inhibitors | MANNKING CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2011056744-A1 | IRE-1 α INHIBITORS | MANNKIND CORPORATION (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072745-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | ERN1 2/4885 |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | ERN1 2/4885 |
| US-20170166576-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | ERN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.